Literature DB >> 8481911

The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography.

C Sung1, R L Dedrick, W A Hall, P A Johnson, R J Youle.   

Abstract

The spatial distribution of i.v. administered immunotoxins in s.c. human rhabdomyosarcoma RD2 xenografts was studied. The toxin and immunotoxins were: (a) diphtheria toxin (DT); (b) a binding-deficient form of DT (CRM107) linked to a monoclonal IgG1 antibody (454A12) directed against the human transferrin receptor (454A12-107); (c) the binding-deficient form of DT linked to the Fab' fragment of 454A12 (Fab'-107); and (d) the binding-deficient form of DT coupled to MOPC21, a monoclonal IgG1 with no significant binding to RD2 cells. DT and the immunotoxins were radiolabeled with 125I and injected via the tail vein into tumor-bearing athymic mice (median tumor weight, 0.25 g). Tumors were removed 2, 6, and 24 h after injection of DT or immunotoxin. Film images of 20-microns frozen sections were digitized by video microscopy, and gray levels were converted to tissue concentrations based upon the film response to radioactivity standards and the specific activity of the radiolabeled toxins. Images of the tumors were characterized quantitatively by the kurtosis and the area above threshold; the kurtosis is a measure of the spatial heterogeneity of the radiolabeled immunotoxins, and the area above threshold is defined here as the fractional tumor area that reaches or exceeds 1.5% of the initial plasma concentration. The spatial distribution of DT in the tumors was extremely uniform, characterized by low kurtosis values. In contrast, the autoradiograms of 454A12-107 were punctate in appearance and were characterized by very high kurtosis values. Fab'-107, which has approximately one-half the molecular weight of the intact immunotoxin and binds only monovalently, also produced punctate images with kurtosis values similar to those for 454A12-107. The nonbinding immunotoxin distributed somewhat less uniformly than DT but much more homogeneously than either of the binding immunotoxins. DT, 454A12-107, and Fab'-107 have similar affinities for their respective receptors, but the concentration of binding sites for DT on RD2 cells (<3,000 receptors/cell) is much lower than the concentration of transferrin receptor (60,000 receptors/cell). Thus, the heterogeneous distribution of 454A12-107 and Fab'-107 probably reflects retarded penetration due to binding to the tumor cells. The area above threshold was greatest for DT and lowest for 454A12-107; the fragment and nonbinding immunotoxins had intermediate values. The lower area above threshold for the nonbinding immunotoxin as compared with DT may be due to the considerably large molecular weight and hence the lower capillary permeability and diffusion coefficient of the immunotoxin.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8481911

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Authors:  Yingzhi Chen; Meng Zhang; Kyoung Ah Min; Huiyuan Wang; Meong Cheol Shin; Feng Li; Victor C Yang; Yongzhuo Huang
Journal:  Curr Drug Targets       Date:  2018-02-19       Impact factor: 3.465

2.  Effects of cellular pharmacology on drug distribution in tissues.

Authors:  R K Rippley; C L Stokes
Journal:  Biophys J       Date:  1995-09       Impact factor: 4.033

3.  Diffusion of an anti-transferrin receptor antibody in cultured murine melanoma cell layers.

Authors:  V Vijaykumar; E M Topp
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

4.  Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature.

Authors:  Yingzhi Chen; Meng Zhang; Hongyue Jin; Yisi Tang; Huiyuan Wang; Qin Xu; Yaping Li; Feng Li; Yongzhuo Huang
Journal:  Biomaterials       Date:  2016-11-27       Impact factor: 12.479

5.  Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms.

Authors:  J F Downing; D L Kachel; R Pasula; W J Martin
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

6.  Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.

Authors:  Seunguk Oh; John R Ohlfest; Deborah A Todhunter; Vincent D Vallera; Walter A Hall; Hua Chen; Daniel A Vallera
Journal:  J Neurooncol       Date:  2009-06-11       Impact factor: 4.130

7.  Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Authors:  Robert J Kreitman; Raffit Hassan; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

8.  Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

Authors:  T Saga; R D Neumann; T Heya; J Sato; S Kinuya; N Le; C H Paik; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

9.  Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug.

Authors:  T L Cheng; S L Wei; B M Chen; J W Chern; M F Wu; P W Liu; S R Roffler
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.